Liquidia Reports Strong Q2 Earnings Driven by YUTREPIA Sales Growth
In its second-quarter earnings call, Liquidia Corporation reported significant financial growth driven primarily by the commercial success of its inhaled therapy YUTREPIA. Net product sales reached $170.4 million, a 31% increase from Q1 2026 due to higher volumes. The company also posted net income of $74.7 million and non-GAAP adjusted EBITDA of $96.3 million. YUTREPIA has gained traction in the market with over 5,000 patients starting therapy since its June 2025 launch and more than 1,100 prescribers involved. The product now holds approximately 30% share of the net revenue-based inhaled treprostinil market. Management is optimistic about future growth, projecting that YUTREPIA will drive over $1 billion in revenue by 2027. Despite strong sales performance, Liquidia faces challenges including rising R&D costs and legal risks related to ongoing litigation around its product patents.
Tickers: $LQDA
Topics: financial_performance pharmaceuticals